Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
A novel mouse model of Sjogren's syndrome:focused on early pathological changes of lacrimal glands
Author Affiliations & Notes
  • Yixuan Li
    Eye institute of Xiamen University, Xiamen, China
    Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
  • Sijie Lin
    Eye institute of Xiamen University, Xiamen, China
  • Wei Li
    Eye institute of Xiamen University, Xiamen, China
  • Guixiu Shi
    Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
  • Footnotes
    Commercial Relationships   Yixuan Li None; Sijie Lin None; Wei Li None; Guixiu Shi None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6531. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yixuan Li, Sijie Lin, Wei Li, Guixiu Shi; A novel mouse model of Sjogren's syndrome:focused on early pathological changes of lacrimal glands. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6531.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Sjögren‘s syndrome (SS) is a chronic inflammatory autoimmune disease characterized by lacrimal gland (LG) and salivary gland (SG) injury. This study aims to establish a mouse model that can accurately simulate the pathological process of SS, characterized by early involvement of the eye symptom.

Methods : The C57/B6J mice were divided into four groups: PBS induction (PBS-in), SG protein induction (SG-in), LG protein induction (LG-in), and LG and SG protein mixture induction (MIX-in). The proteins were mixed with complete Freund's adjuvant, emulsified, and injected subcutaneously into the mice once per week during the first two weeks. From the second week, the mice were immunized every 2 weeks with the protein mixed with incomplete Freund's adjuvant. This immunization was continued until week 24. Corneal changes, tear secretion and salivary secretion were assessed every week. LG and SG samples were subjected to H&E staining, Masson's staining, and immunofluorescence staining to detect the IgG and IgM. The expression of genes such as AQP4, AQP5, and ASMA was analyzed using immunofluorescence and RT-qPCR. Serum levels of antibodies were detected by Elisa.

Results : At week 3, serum level of antibodies began to rise in each induction group. In the LG-in and MIX-in groups, reduced tear secretion, dryness, and epithelial defects were observed Immune damage to the LG has occurred. At week 4 , the LG exhibited inflammatory cell infiltration primarily composed of B lymphocytes. Fibrosis in the LG started to occur, and the expression of the AQP5 decreased. No changes were observed in the SG. At week 14, the LG showed aggravated inflammatory cell infiltration and fibrosis, with continued impairment of secretion function. The SG experienced immune damage. At week 24, the LG presented significant inflammatory cell infiltration, Fibrosis in the lacrimal gland intensified, and the AQP5 continued to decrease, leading to further impairment of secretion function. The SG exhibited inflammatory cell infiltration. SG fibrosis was evident, with reduced expression of the AQP5 and impaired secretion function.

Conclusions : This induction mouse model of SS can simulate changes in serum, LG and SG pathology, enabling the evaluation of early, progressive, and late features of SS. It can provide a research foundation for identifying specific autoantibodies targeting the LG and early diagnosis and treatment targets for SS.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×